This is supported by the finding that pre-symptomatic FTD causing mutant MAPT carriers had intermediate levels of brain atrophy compared to symptomatic carriers but comparable glucose hypometabolism (Deters et al., 2014). Here, MAPT is linked to Brain atrophy.